UTEP researchers identify Claudin-4 protein as a target to improve immune response against aggressive ovarian cancer.

Wistar Institute scientist Maureen Murphy wants to solve a decades-long mystery: Why is ovarian cancer often resistant to ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The ...

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ...

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...

Ovarian cancer, often termed a 'silent killer,' is frequently diagnosed late due to subtle, easily dismissed early symptoms ...

A 132-pound ovarian tumor was removed from a 38-year-old Connecticut woman this year, according to two doctors involved in the case. The patient, who wished to remain anonymous, reported that the ...

PORTLAND, Ore. (KTVZ) – New magnetic nanoparticles in the shape of a cube sandwiched between two pyramids represent a breakthrough for treating ovarian tumors and possibly other types of cancer, ...

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could ...